We are live on
!
Find out more
GSC
G&S Capital Portfolio holdings
AUM
$345M
1-Year Est. Return
32.53%
This Fund
S&P 500
This Quarter
Est. Return
+6.85%
1 Year Est. Return
+32.53%
3 Year Est. Return
+77.18%
5 Year Est. Return
+99.48%
10 Year Est. Return
–
AUM
$238M
AUM Growth
+$8.41M
(+3.7%)
Cap. Flow
-$16.8M
Cap. Flow
% of AUM
-7.03%
Top 10 Holdings %
Top 10 Hldgs %
32.63%
Holding
132
New
13
Increased
58
Reduced
42
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$3.54M |
| 2 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$2.77M |
| 3 |
Colgate-Palmolive
CL
|
+$2.65M |
| 4 |
Danaher
DHR
|
+$2.64M |
| 5 |
Cirrus Logic
CRUS
|
+$2.35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$18.2M |
| 2 |
Pfizer
PFE
|
+$2.8M |
| 3 |
Illinois Tool Works
ITW
|
+$2.62M |
| 4 |
Lam Research
LRCX
|
+$2.54M |
| 5 |
Constellation Energy
CEG
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 10.13% |
| 2 | Financials | 8.52% |
| 3 | Industrials | 6.71% |
| 4 | Healthcare | 4.12% |
| 5 | Energy | 3.93% |
Similar funds
OPW
PFMOSF
AIM
ICM
SEEDPG
GLCM
VW
FFA
G&S Capital's Q3 2024 Portfolio in Review
As of Q3 2024, G&S Capital held 132 positions worth $238M, up 3.7% from $230M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
G&S Capital withdrew a net $16.8M in Q3 2024, closing 13 positions and reducing 42 holdings. Its most notable exit was Pfizer, an estimated $2.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 10% of assets, down from 12% a quarter earlier, followed by Financials and Industrials.
Against the trend, G&S Capital opened a new position in Invesco S&P 500 Equal Weight ETF worth $2.91M.
- G&S Capital's largest Q3 2024 buy was Invesco S&P 500 Equal Weight ETF: 16,230 shares worth $2.91M.
- G&S Capital added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q3 2024, an estimated $3.54M increase.
- G&S Capital's biggest Q3 2024 reduction was Broadcom, cutting an estimated $18.2M.
- G&S Capital fully exited Pfizer in Q3 2024, selling an estimated $2.8M.
- G&S Capital's ten largest holdings make up 33% of its $238M portfolio in Q3 2024.
- G&S Capital opened 13 new positions and closed 13 in Q3 2024.
- G&S Capital's portfolio value rose 3.7% quarter-over-quarter to $238M.
Based on G&S Capital's 13F filing for Q3 2024, filed 16 Oct 2024.